BEAM - Rally for gene editing stocks continues into third day boosted by Intellia

PhonlamaiPhoto/iStock via Getty Images Biotech companies that are focused on the gene editing space for treatments are continuing higher for the third straight day. Beam Therapeutics ([[BEAM]] +15.7%) and Editas Medicine ([[EDIT]] +16.6%) are up double-digit percentages. CRISPR Therapeutics ([[CRSP]] +8.1%), bluebird bio ([[BLUE]] +6.1%), and Sangamo Therapeutics ([[SGMO]] +4.6%) are up single-digit percentages. The ARK Genomic Revolution Multi-Sector ETF ([[ARKG]] +0.2%) is barely higher. The best performing gene editing stock so far today is Intellia Therapeutics ([[NTLA]] +22.4%). The stock has had massive gains this week following a significant development in one of its CRISPR candidates.

For further details see:

Rally for gene editing stocks continues into third day, boosted by Intellia